Eli Lilly is receiving stronger Wall Street support as Berenberg upgraded the stock to Buy from Hold and raised its price target to $1,400 from $1,220, implying 23% upside from Monday’s close. The firm expects Eli Lilly to maintain its lead in the fast-growing obesity market, potentially exceed fiscal 2026 guidance and benefit from pipeline investments funded by the success of its weight-loss medicines. Shares have gained 52% over the past year as demand grows for GLP-1 treatments. Eli Lilly sells Mounjaro for blood-sugar control and Zepbound for patients with weight-related health conditions. Berenberg also cited the anticipated diabetes approval of Foundayo, an oral GLP-1 drug, and said several pipeline candidates could generate multibillion-dollar sales. The latest LSEG data shows 27 of 34 analysts rate the stock Buy or Strong Buy. Citigroup’s existing $1,600 target remains the highest cited in the record, implying about 45% upside from the previously reported $1,138 trading level.